Researchers at Tuojie Biotech (Shanghai) Co. Ltd. have developed substituted 1,4-dihydro-1,6-naphthyridine amides characterized as mineralocorticoid receptor (MR) antagonists and reported to be useful for the treatment of hypertension, aldosteronism and heart failure.